Dhipatimendi rePasi Pose

Musi wa17 Chikunguru, Center for Drug Evaluation (CDE) yeNational Medical Products Administration (NMPA) yakazivisa kuti chikumbiro chekushambadzira cheTrastuzumab Deruxtecan (Enhertu®) chekurapa kenza yemudumbu chechipiri chagamuchirwa zviri pamutemo neNMPA. Chikumbiro ichi chinoshanda...Verenga zvakawanda»

Munguva pfupi yapfuura, Ascentage Pharma yakazivisa kuti mushonga wayo mutsva weBcl-2 selective inhibitor lisaftoclax (APG-2575) wakatenderwa neChina's National Medical Products Administration (NMPA) kurapa varwere vakuru vane chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)...Verenga zvakawanda»

Munguva pfupi yapfuura, GenFleet Therapeutics yakazivisa kuti Pharmaceutical Administration Bureau (ISAF) yeMacau Special Administrative Region yeChina yabvumidza Dupert® (fulzerasib, GFH925/IBI351) yekurapa varwere vane advanced non-small cell lung cancer (NSCLC) vane KRAS G12C mutati...Verenga zvakawanda»

Musi wa30 Chikumi, mushonga weAvistone weMET inhibitor Vebreltinib wakagadzirwa wega wakapihwa mvumo kubva kuNational Medical Products Administration (NMPA) yekuChina yekurapa varwere vane kenza yemapapu isina masero madiki (NSCLC) ine MET amplifies...Verenga zvakawanda»

Musi wa30 Chikumi, 2025, HUTCHMED yakazivisa kuti New Drug Application (NDA) yemusanganiswa weORPATHYS (savolitinib) neTAGRISSO (osimertinib) yapihwa mvumo neChina National Medical Products Administration (NMPA) yekurapa varwere vane mishonga yepamusoro kana kuti metastasis munharaunda...Verenga zvakawanda»

Musi wa30 Chikumi, webhusaiti yepamutemo yeNational Medical Products Administration (NMPA) yakazivisa kuti Anlotinib, mushonga mutsva weKirasi 1 wakagadzirwa naChia Tai Tianqing, wagamuchira mvumo yechiratidzo chitsva muChina: kurapa kwakabatana nechemotherapy yekurapa varwere vekutanga ...Verenga zvakawanda»

Musi wa26 Chikumi, 2025, CARsgen yakazivisa kuti National Medical Products Administration (NMPA) yeChina yagamuchira New Drug Application (NDA) ye satricabtagene autoleucel ("satri-cel", CT041) (chigadzirwa cheCAR T-cell chinogadzirwa neprotein Claudin18.2) chekurapa Claudi...Verenga zvakawanda»

Musi wa19 Chikumi, Center for Drug Evaluation (CDE) yeNational Medical Products Administration (NMPA) yakazivisa kuti jekiseni reLM-108 reLivzon Pharmaceutical rakurudzirwa kuti rivepo muchirongwa chekurapa kwekubudirira. Kusanganiswa kweKefeqibai monoclonal antibody injection (LM-1...Verenga zvakawanda»

Musi wa19 Chikumi, Center for Drug Evaluation (CDE) yeNational Medical Products Administration (NMPA) yakazivisa kuti IBI343 yeInnovent Biologics yakakurudzirwa kuti ibatanidzwe muchirongwa chekurapa kwakabudirira, chakagadzirirwa kurapa pan yepamusoro kana kuti yakapararira munzvimbo iyoyo...Verenga zvakawanda»

Musi wa6 Chikumi, magazini yepasi rose yezvekurapa inonzi Journal of Hematology & Oncology yakaburitsa mhedzisiro yechidzidzo chechikamu chekutanga/chipiri (KL264-01/MK-2870-001) cheTROP2 ADC sacituzumab tirumotecan (sac-TMT) senzira yekurapa chete maronda akaomarara asingabvisike kana kuti anoramba kupararira kwemasero emumuviri.Verenga zvakawanda»

Musi wa10 Chikumi, Center for Drug Evaluation (CDE) yeNational Medical Products Administration (NMPA) yakazivisa kuti Trastuzumab Deruxtecan (T-DXd, DS-8201a) inokurudzirwa kuti iongororwe zvakanyanya pakurapa varwere vakuru vane chirwere chemudumbu cheHER2-positive chiri munzvimbo yavo kana kuti chakapararira...Verenga zvakawanda»

Munguva pfupi yapfuura, Merck & Co., Inc. (Merck) yakazivisa kuti mushonga wayo wePD-1 inhibitor, pembrolizumab, wabvumidzwa neNational Medical Products Administration (NMPA) yekuChina kuti ushandiswe pamwe chete nelenvatinib uye transarterial chemoembolization (TACE) pakurapa varwere vane utachiona husina hutachiona...Verenga zvakawanda»